Author

M. Falqués

Observed names: M Falques, M Falqués, M. Falques, Mertixell Falques

OpenAlex ID: A5110744117

Early vs. Non-Early Intervention in Acute Migraine — ‘Act When Mild (AwM)’. A Double-Blind, Placebo-Controlled Trial of Almotriptan

2008 · PJ Goadsby, G Zanchin, et al. · Cephalalgia · 219

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial

2021 · B.M. Piraccini, U. Blume‐Peytavi, et al. · Journal of the European Academy of Dermatology and Venereology · 199

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

2019 · K. Reich, R.B. Warren, et al. · British Journal of Dermatology · 149

PDF

Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints

2012 · E. M. M. Quigley, J. Tack, et al. · Alimentary Pharmacology & Therapeutics · 127

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

2021 · D. Thaci, S. Piaserico, et al. · British Journal of Dermatology · 103

PDF

Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD

2009 · H. Magnussen, H. Watz, et al. · Respiratory Medicine · 69

PDF

The Impact of Allodynia on the Efficacy of Almotriptan When Given Early in Migraine: Data From the “Act When Mild” Study

2011 · S. Díaz-Insa, P. J. Goadsby, et al. · International Journal of Neuroscience · 23

Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate ( DMF ): a post hoc analysis of the BRIDGE study

2019 · P.C.M. van de Kerkhof, R. Loewe, et al. · Journal of the European Academy of Dermatology and Venereology · 22

PDF

Use of reflectance confocal microscopy to evaluate 5‐fluorouracil 0.5%/salicylic acid 10% in the field‐directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III , randomized, double‐blind, vehicle‐controlled trial

2017 · M. Ulrich, U. Reinhold, et al. · Journal of the European Academy of Dermatology and Venereology · 11

PWE-175 Cost-effectiveness Of Linaclotide (lin) Compared To Antidepressants (atds) In The Treatment Of Irritable Bowel Syndrome With Constipation (ibs-c) In Scotland

2014 · M Fisher, A Walker, et al. · Gut · 1

PDF

Cost-Effectiveness of Linaclotide Compared to Antidepressants in the Treatment of Irritable Bowel Syndrome with Constipation in Scotland

2013 · M. Fisher, M. Falqués, et al. · Value in Health · 1

OC-082 26-Week efficacy and safety of once-daily oral linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a European perspective

2012 · A J Lembo, J Fortea, et al. · Gut · 1

PDF

Profil de sécurité du lébrikizumab chez les adultes et les adolescents atteints de dermatite atopique modérée à sévère : données de sécurité intégrées au RCP

2025 · M.D. Bruin-Weller, S. Barbarot, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Le lébrikizumab améliore les signes et symptômes de la dermatite atopique modérée à sévère chez les patients insuffisamment contrôlés ou inéligibles à la ciclosporine : résultats à la semaine 52 d’une étude clinique de phase 3 (ADvantage)

2024 · R.B. Warren, M.D. Bruin-Weller, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Efficacité et sécurité du lébrikizumab en combinaison avec des dermocorticoïdes chez des patients souffrant de dermatite atopique modérée à sévère non-contrôlée ou non-éligibles à la ciclosporine: premiers résultats d’un essai de phase 3 (ADvantage)

2023 · R.B. Warren, M. De Bruin-Weller, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Le lébrikizumab fournit une réponse à long-terme cliniquement significative chez des patients atteints de dermatite atopique modérée à sévère

2023 · C. Vestergaard, S. Weidinger, et al. · Annales de Dermatologie et de Vénéréologie - FMC

Le lébrikizumab réduit l’étendue et la sévérité de la dermatite atopique dans différentes régions du corps, y compris la topographie tête et cou

2023 · E.L. Simpson, G. Honari, et al. · Annales de Dermatologie et de Vénéréologie - FMC

395 Assessing imputation methods with the lebrikizumab clinical trial program

2023 · April W Armstrong, Jonathan I Silverberg, et al. · British Journal of Dermatology

A study of the drug tildrakizumab in psoriasis patients

2020 · K. Reich, R.B. Warren, et al. · British Journal of Dermatology

PTU-187 Sample size calculation in confirmatory trials in irritable bowel syndrome with constipation: experience with linaclotide (constella®)

2015 · M Falques, C Díaz, et al. · Gut

PTU-185 Treatment satisfaction after retreatment and long-term therapy with linaclotide (constella®)

2015 · C Díaz, M Falques, et al. · Gut

PTU-186 Baseline characteristics as a predictor of response to linaclotide (constella®) in patients with irritable bowel syndrome with constipation: a pooled analysis of 2 phase 3 trials

2015 · C Díaz, M Falques, et al. · Gut

PTU-188 Statistical approaches to missing data in trials of irritable bowel syndrome with constipation: experience with linaclotide (constella®)

2015 · M Falques, C Díaz, et al. · Gut

Linaclotid verbessert signifikant abdominelle Schmerzen und Darmsymptome bei Patienten mit Reizdarmsyndrom und Obstipation (RDS-O): Europäische Auswertung einer Phase 3 Studie

2012 · E Quigley, A Lembo, et al. · Zeitschrift für Gastroenterologie

PTU-152 Significant improvements in abdominal pain and bowel symptoms in a phase 3 trial of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a European perspective

2012 · E M Quigley, A J Lembo, et al. · Gut

PDF

Works count: 25

Citation count: 925

H-index: 9

I10-index: 9